Back to Agenda
Session 5 Track A: Clinical Experience with Lipid Nanoparticle- Based Delivery of Oligonucleotides
Session Chair(s)
Christine Swenson
Head, Global Regulatory Affairs, Moderna Therapeutics, United States
Delivery of oligonucleotides using lipid nanoparticles (LNP) has been an emerging area of interest over the past decade. Clinical progress with LNP-mediated delivery of siRNAs, mRNAs, and saRNAs will be discussed.
Learning Objective :
At the conclusion of this session, participants should be able to:
- Understand the use of LNP approaches for delivery of various oligonucleotides
- Become familiar with clinical efficacy and safety using this modality for different diseases
Speaker(s)
Pushkal Garg
, Alnylam Pharmaceuticals, Inc., United States
Development and Approval of ONPATTRO, the First RNAi Therapeutic
Christine Swenson
Head, Global Regulatory Affairs, Moderna Therapeutics, United States
Emerging Clinical Data for Intratumor and Systemic Administration of mRNA Therapies
Nagy Habib, MD, PhD
Head of Research and Development, MiNA Therapeutics Limited , United Kingdom
MTL-CEBPA, The First Small Activating RNA Therapy in Clinical Development
Have an account?